Replies to post #143425 on Cytodyn Inc (CYDY)

[Monroe1]

Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use
BY GlobeNewswire
— 4:01 PM ET 01/29/2021

CytoDyn ( CYDY) will dedicate at least 200,000 vials (100,000 doses) of leronlimab from its inventory to Chiral Pharma Corp. for potential sales in the Philippines

VANCOUVER, Washington, Jan. 29, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. ( CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it is working with Chiral Pharma Corp. in the Philippines to register Vyrologix™ under a licensed physician’s request for Compassionate Special Permit (CSP) to treat COVID-19 patients with leronlimab for a fee. Last night, the CytoDyn ( CYDY) team presented the results from various studies (primarily from U.S. eIND patients) of leronlimab as a potential therapeutic for COVID-19 patients to several Philippine regulators, hospital executives and physicians. Drs. Seethamraju and Agresti discussed their patient experiences with leronlimab for critical COVID-19 patients under eIND. References were also made to several published papers by Drs. Otto Yang and Nicholas Agresti, among others, for the treatment of COVID-19 patients with leronlimab.